ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

Henderson Committee Final Recommendation Made On P01s

February 10, 1984

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994

Chabner Object To Yarbro’s Remarks On Federal Role In Clinical Research

April 15, 1983

ONS Opposes AMA On “Registered Care Technologist”

August 19, 1988